Well that is disappointing
“The study did not meet its primary efficacy endpoint of MACE reduction at 90 days. As a result, there are no plans for a near-term regulatory filing. There were no major safety or tolerability concerns with CSL112.”
the leading health company stumbles again.
Ann: Top-line Results from the Phase 3 AEGIS-II Trial, page-25
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$289.50 |
Change
3.640(1.27%) |
Mkt cap ! $139.9B | |||
| Open | High | Low | Value | Volume |
| $288.00 | $290.59 | $287.50 | $187.6M | 648.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1047 | $289.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $289.50 | 999 | 1 |
View Market Depth
| Last trade - 16.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$290.04 |
Change
3.640 ( 1.50 %) |
||||
| Open | High | Low | Volume | ||
| $288.03 | $290.59 | $287.95 | 32855 | ||
| Last updated 15.59pm 06/06/2024 ? | |||||
| CSL (ASX) Chart |